Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice

Reproductive Toxicology

Volumn 32, Issue 4, 2011, Pages 385-394

  Khan, Sabbir ^a   Ahmad, Tauseef ^a   Parekh, Chintan Vishnubhai ^a   Trivedi, Priyanka Pushkarbhai ^a   Kushwaha, Sapana ^a   Jena, Gopabandhu ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Genotoxicity; Germ cell; Mice; Oxidative stress; Sodium valproate

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DNA; GLUTATHIONE; MALONALDEHYDE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DAMAGE; COMET ASSAY; DNA DAMAGE; EPIDIDYMIS; GENOTOXICITY; GERM CELL; HISTOLOGY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; SPERMATOZOON; SPERMATOZOON COUNT; TESTIS WEIGHT;

ANIMALS; ANTICONVULSANTS; DEOXYGUANOSINE; DNA DAMAGE; EPIDIDYMIS; MALE; MICE; MUTAGENS; ORGAN SIZE; OXIDATIVE STRESS; SPERM COUNT; SPERM HEAD; SPERMATOZOA; TESTIS; VALPROIC ACID;

ANIMALIA; MUS;

EID: 80055014296     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2011.09.007     Document Type: Article

References (55)

1. Davis R., Peters D.H., McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994, 47:332-372.
2. Nasrallah H.A., Ketter T.A., Kalali A.H. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J Affect Disord 2006, 95:69-78.
3. Krymchantowski A.V., Bigal M.E., Moreira P.F. New and emerging prophylactic agents for migraine. CNS Drugs 2002, 16:611-634.
4. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16:695-714.
5. Aldemir E., Akdeniz F. Effects of valproate on male reproductive functions. Turk J Psychiatry 2009, 20:376-384.
6. Isojarvi J.I., Lofgren E., Juntunen K.S., Pakarinen A.J., Paivansalo M., Rautakorpi I., et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 2004, 62:247-253.
7. Krogenaes A.K., Tauboll E., Stien A., Oskam I.C., Lyche J.L., Dahl E., et al. Valproate affects reproductive endocrine function, testis diameter and some semen variables in non-epileptic adolescent goat bucks. Theriogenology 2008, 70:15-26.
8. Nishimura T., Sakai M., Yonezawa H. Effects of valproic acid on fertility and reproductive organs in male rats. J Toxicol Sci 2000, 25:85-93.
9. Sveberg Roste L., Tauboll E., Berner A., Berg K.A., Aleksandersen M., Gjerstad L. Morphological changes in the testis after long-term valproate treatment in male Wistar rats. Seizure 2001, 10:559-565.
10. Sveberg Roste L., Tauboll E., Isojarvi J.I., Pakarinen A.J., Huhtaniemi I.T., Knip M., et al. Effects of chronic valproate treatment on reproductive endocrine hormones in female and male Wistar rats. Reprod Toxicol 2002, 16:767-773.
11. Chateauvieux S., Morceau F., Dicato M., Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010:1-18.
12. Kostrouchova M., Kostrouch Z., Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 2007, 53:37-49.
13. Roste L.S., Tauboll E., Morkrid L., Bjornenak T., Saetre E.R., Morland T., et al. Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy. Eur J Neurol 2005, 12:118-124.
14. Snyder P.J., Badura L.L. Chronic administration of sodium valproic acid slows pubertal maturation in inbred DBA/2J mice: skeletal, histological, and endocrinological evidence. Epilepsy Res 1995, 20:203-211.
15. Cengiz M., Yuksel A., Seven M. The effects of carbamazepine and valproic acid on the erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children. Pharmacol Res 2000, 41:423-425.
16. Pippenger C.E. Therapeutic drug monitoring in the 1990s. Clin Chem 1989, 35:1348-1351.
17. Tabatabaei A.R., Thies R.L., Abbott F.S. Assessing the mechanism of metabolism-dependent valproic acid-induced in vitro cytotoxicity. Chem Res Toxicol 1999, 12:323-330.
18. Aitken R.J., De Iuliis GN On the possible origins of DNA damage in human spermatozoa. Mol Hum Reprod 2010, 16:3-13.
19. Aitken R.J., Gordon E., Harkiss D., Twigg J.P., Milne P., Jennings Z., et al. Relative impact of oxidative stress on the functional competence and genomic integrity of human spermatozoa. Biol Reprod 1998, 59:1037-1046.
20. Schulpis K.H., Lazaropoulou C., Regoutas S., Karikas G.A., Margeli A., Tsakiris S., et al. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006, 217:228-232.
21. Arce C., Perez-Plasencia C., Gonzalez-Fierro A., de la Cruz-Hernandez E., Revilla-Vazquez A., Chavez-Blanco A., et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006, 1:e98.
22. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008, 34:206-222.
23. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
24. Moron M.S., Depierre J.W., Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 1979, 582:67-78.
25. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
26. Vikram A., Tripathi D.N., Ramarao P., Jena G.B. Intervention of d-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicol Appl Pharmacol 2008, 226:84-93.
27. Glander H.J., Horn L.C., Dorschner W., Paasch U., Kratzsch J. Probability to retrieve testicular spermatozoa in azoospermic patients. Asian J Androl 2000, 2:199-205.
28. Almeida F.F., Leal M.C., Franca L.R. Testis morphometry, duration of spermatogenesis, and spermatogenic efficiency in the wild boar (Sus scrofa scrofa). Biol Reprod 2006, 75:792-799.
29. Burruel V.R., Yanagimachi R., Whitten W.K. Normal mice develop from oocytes injected with spermatozoa with grossly misshapen heads. Biol Reprod 1996, 55:709-714.
30. Wyrobek A.J., Bruce W.R. Chemical induction of sperm abnormalities in mice. Proc Natl Acad Sci USA 1975, 72:4425-4429.
31. Haines G.A., Hendry J.H., Daniel C.P., Morris I.D. Germ cell and dose-dependent DNA damage measured by the comet assay in murine spermatozoa after testicular X-irradiation. Biol Reprod 2002, 67:854-861.
32. Tripathi D.N., Jena G.B. Astaxanthin inhibits cytotoxic and genotoxic effects of cyclophosphamide in mice germ cells. Toxicology 2008, 248:96-103.
33. Binkerd P.E., Rowland J.M., Nau H., Hendrickx A.G. Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Daley rats. Fundam Appl Toxicol 1988, 11:485-493.
34. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?. Reprod Toxicol 2009, 28:1-10.
35. Wagner P.G., Welton S.R., Hammond C.M. Gastrointestinal adverse effects with divalproex sodium and valproic acid. J Clin Psychiatry 2000, 61:302-303.
36. Wulff K., Flachs H., Wurtz-Jorgensen A., Gram L. Clinical pharmacological aspects of valproate sodium. Epilepsia 1977, 18:149-157.
37. El-Khatib F., Rauchenzauner M., Lechleitner M., Hoppichler F., Naser A., Waldmann M., et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007, 16:226-232.
38. Gaspari C.N., Guerreiro C.A. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr 2010, 68:277-281.
39. Aitken R.J., Baker M.A. Oxidative stress and male reproductive biology. Reprod Fertil Dev 2004, 16:581-588.
40. Sharma R.K., Said T., Agarwal A. Sperm DNA damage and its clinical relevance in assessing reproductive outcome. Asian J Androl 2004, 6:139-148.
41. Sikka S.C. Relative impact of oxidative stress on male reproductive function. Curr Med Chem 2001, 8:851-862.
42. Chang T.K., Abbott F.S. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev 2006, 38:627-639.
43. Kaneko T., Tahara S., Matsuo M. Non-linear accumulation of 8-hydroxy-2'-deoxyguanosine, a marker of oxidized DNA damage, during aging. Mutat Res 1996, 316:277-285.
44. Leinonen J., Lehtimaki T., Toyokuni S., Okada K., Tanaka T., Hiai H., et al. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett 1997, 417:150-152.
45. Shen H., Ong C. Detection of oxidative DNA damage in human sperm and its association with sperm function and male infertility. Free Radic Biol Med 2000, 28:529-536.
46. Sun F., Ko E., Martin R.H. Is there a relationship between sperm chromosome abnormalities and sperm morphology?. Reprod Biol Endocrinol 2006, 4:1.
47. Trivedi P.P., Kushwaha S., Tripathi D.N., Jena G.B. Evaluation of male germ cell toxicity in rats: correlation between sperm head morphology and sperm comet assay. Mutat Res 2010, 703:115-121.
48. Aitken R.J., De Iuliis G.N. Origins and consequences of DNA damage in male germ cells. Reprod Biomed Online 2007, 14:727-733.
49. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269:7-17.
50. Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 2005, 84:109-121.
51. Barratt C.L., Aitken R.J., Bjorndahl L., Carrell D.T., de Boer P., Kvist U., et al. Sperm DNA: organization, protection and vulnerability: from basic science to clinical applications-a position report. Hum Reprod 2010, 25:824-838.
52. Carrell D.T., Hammoud S.S. The human sperm epigenome and its potential role in embryonic development. Mol Hum Reprod 2010, 16:37-47.
53. Trasler J.M. Epigenetics in spermatogenesis. Mol Cell Endocrinol 2009, 306:33-36.
54. Rocca A., Minucci S., Tosti G., Croci D., Contegno F., Ballarini M., et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009, 100:28-36.
55. Atmaca A., Al-Batran S.E., Maurer A., Neumann A., Heinzel T., Hentsch B., et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007, 97:177-182.